Alumis (NASDAQ:ALMS - Get Free Report)'s stock had its "buy" rating reiterated by equities researchers at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $26.00 price target on the stock. HC Wainwright's price target would indicate a potential upside of 194.78% from the stock's current price.
A number of other equities analysts have also recently weighed in on ALMS. Robert W. Baird assumed coverage on shares of Alumis in a research report on Thursday, October 31st. They set an "outperform" rating and a $25.00 price target on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. Finally, Baird R W upgraded Alumis to a "strong-buy" rating in a report on Thursday, October 31st. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $26.83.
Check Out Our Latest Report on Alumis
Alumis Price Performance
Alumis stock traded up $0.19 during midday trading on Friday, hitting $8.82. 404,401 shares of the stock were exchanged, compared to its average volume of 151,245. The firm has a fifty day moving average price of $10.24. Alumis has a 52 week low of $7.66 and a 52 week high of $13.53.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets bought a new position in Alumis in the third quarter valued at $27,000. MetLife Investment Management LLC acquired a new position in shares of Alumis during the 3rd quarter worth about $89,000. Barclays PLC bought a new position in shares of Alumis in the 3rd quarter valued at about $197,000. Maven Securities LTD bought a new position in shares of Alumis in the 2nd quarter valued at about $332,000. Finally, State Street Corp acquired a new stake in shares of Alumis in the third quarter valued at about $866,000.
Alumis Company Profile
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
